Narcolepsy Treatment Market Research Report, Share, and Forecast to 2025

Posted by rekha on November 4th, 2019

“The Global Narcolepsy Treatment Market was valued at US$ 2,571.8 Mn in 2018 and is expected to grow at a significant CAGR over six years forecast period 2019-2025 owing to rising prevalence of obstructive sleep apnea and its comorbidities”

Precision Business Insights (PBI) in its report titled “Global Narcolepsy Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2018 and Forecast 2019-2025” assesses the market performance over six years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

The global narcolepsy treatment market was valued at US$ 2,571.8 Mn in 2018 and growing at a CAGR of 8.1% over the forecast period owing to rising incidence of several sleeping disorders that includes narcolepsy, upsurge in awareness regarding the sleep disorders. In addition, growing demand for advanced diagnostics and therapeutics to treat narcolepsy and growth in elderly people. A narcoleptic disorder is proportionally prevailing to Parkinson’s disease, according to the World Health Organization statistics, more than 3 million people are suffering from narcolepsy globally. However, lack of awareness among the under-developed economies, stringent regulatory structure, and abuse of the drugs, late or undiagnosed narcolepsy patients are the major factors hampering the growth of the market.

Global narcolepsy treatment market segmented on the basis of drugs, type of disorder, distribution channel, and region.

Request for Sample Report @ https://www.precisionbusinessinsights.com/request-sample?product_id=16872

Selective serotonin reuptake inhibitor segment accounted for higher revenue share

Based on drugs, global narcolepsy treatment market is segmented into Amphetamines, Methylphenidate, Modafinil, MAO-B Inhibitors (Selegiline), Tricyclic Anti-Depressants (TCA), Selective Serotonin Reuptake Inhibitors (SSRI), and Monoamine Oxidase Type-A (MAO-A) inhibitors. Selective serotonin reuptake inhibitors (SSRIs) segment accounted for the largest market share in 2018 and is expected to grow with highest CAGR over the forecast period owing to increasing investments in research and development for the development of the products and rising prevalence of narcolepsy across the globe is expected to drive the growth of the market over the forecast period.

North America holds leading position in Global Narcolepsy Treatment Market

PBI’s global narcolepsy treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to regional analysis, North America is expected to account for larger revenue share in 2018 and the same trend is projected to follow over 2019-2025 owing to increase in number of narcolepsy and other sleep disorder cases in the United States. According to the American Academy of Sleep Medicine, around 1 in approximately 2,000 people in the USA are suffered from narcolepsy. Asia-Pacific is predicted to grow with highest CAGR in narcolepsy drugs market, owing to surge in the incidence of narcolepsy and increase in adoption rate of narcolepsy drugs.

Recent Developments in the Global Narcolepsy Treatment Market

• In March 2019, Jazz Pharmaceuticals announced U.S. FDA approval for Sunosi (solriamfetol) for excessive daytime sleepiness associated with Narcolepsy or Obstructive sleep apnea
• In January 2017, Jazz pharmaceuticals received U.S.FDA approval for the first generic version of Xyrem to treat narcolepsy patients.
• In September 2016, Ligand Pharmaceuticals out-licenses 4 development programs to Seelos Therapeutics, that including its H3 receptor antagonist program for narcolepsy, Aplindore program for various CNS disorders, CRTH2 antagonist program for respiratory disorders, Captisol enabled acetaminophen program for fever and pain management.

Key player’s profiles in the report are Arena Pharmaceuticals, Inc. (U.S), Inc., BIOPROJET, Evotec AG (Germany), Graymark Healthcare, Inc. (U.S), Hypnion, Inc. (U.S), Ligand Pharmaceuticals, Inc. (U.S), Teva Pharmaceutical Industries Ltd. (Israel) and Jazz Pharmaceuticals, Inc.,(Ireland).

Detailed Segmentation

By Drugs     

o   Amphetamines

o   Methylphenidate

o   Modafinil

o   MAO-B Inhibitors (Selegiline)

o   Tricyclic Anti-Depressants (TCA)

o   Selective Serotonin Reuptake Inhibitors (SSRI)

o   Monoamine Oxidase Type-A (MAO-A) inhibitors

By Type of Disorder

o   Secondary Narcolepsy

o   Narcolepsy with cataplexy

o   Narcolepsy without cataplexy

 By Distribution Channel

o   Hospital pharmacies

o   Retail Pharmacies

o   Online Pharmacies

Geography

o     North America

• U.S
• Canada

o     Europe

• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe

o     Asia-Pacific

• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific

o     Latin America

• Brazil
• Mexico
• Argentina
• Venezuela
• Rest of Latin America

o     Middle East and Africa (MEA)

• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA

For more information: https://www.precisionbusinessinsights.com/market-reports/global-narcolepsy-treatment-market/